226 related articles for article (PubMed ID: 10863108)
21. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
23. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Bell JM; Turnidge JD; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
[TBL] [Abstract][Full Text] [Related]
24. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Biedenbach DJ; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
[TBL] [Abstract][Full Text] [Related]
26. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Gales A; Sader H; Jones RN;
Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
[TBL] [Abstract][Full Text] [Related]
27. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
28. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
Smayevsky J; Lopez H; Di Chiara M; Scarano S; Lanza A; Vilches V; Stepanik D; Bantar C; Sucari A
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):261-4. PubMed ID: 10974577
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Hoban DJ; Zhanel GG; Karlowsky JA
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):37-44. PubMed ID: 10529880
[TBL] [Abstract][Full Text] [Related]
31. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
Rittenhouse S; McCloskey L; Broskey J; Niconovich N; Jakielaszek C; Poupard J; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
[TBL] [Abstract][Full Text] [Related]
32. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Biedenbach DJ; Barrett MS; Croco MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
[TBL] [Abstract][Full Text] [Related]
33. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
35. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
[TBL] [Abstract][Full Text] [Related]
36. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
37. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Karlowsky JA; Thornsberry C; Critchley IA; Jones ME; Evangelista AT; Noel GJ; Sahm DF
Antimicrob Agents Chemother; 2003 Jun; 47(6):1790-7. PubMed ID: 12760850
[TBL] [Abstract][Full Text] [Related]
38. The incidence of respiratory tract pathogens and antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated between 1990 and 1993.
Nishioka K; Ogihara H; Ohno I; Tanno Y; Shirato K
Tohoku J Exp Med; 1996 Jun; 179(2):111-21. PubMed ID: 8875767
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
40. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
